Novavax COVID-19 vaccine authorized in U.S. as booster for adults
Carsten Koall/Getty Images News


Novavax, Inc. (NASDAQ:NVAX) shares spiked in the morning hours Wednesday after the company announced that the FDA issued emergency use authorization (EUA) for its COVID-19 vaccine for use as a booster shot in those aged 18 years and older.

According to the company, the protein-based vaccine will be allowed as a booster dose at least six months after the primary vaccination with any FDA-authorized COVID-19 vaccine.
It can be used in situations where individuals cannot access mRNA bivalent COVID-19 booster vaccines from Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) or for those the updated vaccines are not indicated, NVAX said.
Commenting on the decision, Novavax Chief Executive Stanley Erck noted that use of Novavax (NVAX) vaccine as a booster will help raise booster vaccination rates at a time when nearly 50% of U.S. adults have yet to receive their booster dose.

In July, the FDA granted EUA for Novavax (NVAX) COVID-19 vaccine for primary vaccination in adults.